© 2018 BJS Society Ltd Published by John Wiley & Sons Ltd Background: In patients with multiple endocrine neoplasia type 2 (MEN2) syndrome, genetic testing offers early diagnosis, stratifies the risk of developing medullary thyroid cancer (MTC) and informs the timing of thyroidectomy. The efficacy of treatment, which depends on timely and safe surgery, is not well established. Methods: This was a retrospective review of diagnostic and clinicopathological outcomes of prophylactic thyroidectomy in children with MEN2 between 1995 and 2013 in the UK. American Thyroid Association (ATA) 2009 guidelines were used as a benchmark for adequate treatment. Results: Seventy-nine children from 16 centres underwent total thyroidectomy. Thirty-eight patien...
Multiple Endocrine Neoplasia 2 (MEN2) is a hereditary cancer syndrome for developing medullary thyro...
RET proto-oncogene predisposing to multiple endocrine neoplasia type IIa (MEN-IIa) has allowed a DNA...
International audienceBackground:In hereditary medullary thyroid carcinoma (HMTC), prophylactic surg...
Background In patients with multiple endocrine neoplasia type 2 (MEN2) syndrome, genetic testing of...
OBJECTIVE: Evaluation of treatment of children who are proven carriers of a multiple endocrine neopl...
Department of Surgery, University Hospital of Maastricht, The Netherlands.BACKGROUND: Patients with ...
Aims: Germline mutated RET proto-oncogene, causing multiple endocrine neoplasia (MEN)-2a syndrome is...
Background: The surgical management of patients with multiple endocrine neoplasia-2A (MEN-2A) contin...
Abstract PURPOSE: Hereditary medullary thyroid carcinoma (MTC) therapy is surgical resection. Beca...
Contains fulltext : 88633.pdf (publisher's version ) (Closed access)BACKGROUND Mul...
textabstractBackground Multiple endocrine neoplasia type 2 (MEN 2) is caused by a RET mutation in ch...
Multiple endocrine neoplasia type 2 (MEN 2) is caused by a RET mutation in chromosome 10. All MEN 2 ...
AIMS: To evaluate the value of prophylactic total thyroidectomy in multiple endocrine neoplasia 2a (...
Multiple endocrine neoplasia type 2 (MEN 2) is caused by a RET mutation in chromosome 10. All MEN 2 ...
Multiple endocrine neoplasia (MEN) syndromes are characterized by the association of various endocri...
Multiple Endocrine Neoplasia 2 (MEN2) is a hereditary cancer syndrome for developing medullary thyro...
RET proto-oncogene predisposing to multiple endocrine neoplasia type IIa (MEN-IIa) has allowed a DNA...
International audienceBackground:In hereditary medullary thyroid carcinoma (HMTC), prophylactic surg...
Background In patients with multiple endocrine neoplasia type 2 (MEN2) syndrome, genetic testing of...
OBJECTIVE: Evaluation of treatment of children who are proven carriers of a multiple endocrine neopl...
Department of Surgery, University Hospital of Maastricht, The Netherlands.BACKGROUND: Patients with ...
Aims: Germline mutated RET proto-oncogene, causing multiple endocrine neoplasia (MEN)-2a syndrome is...
Background: The surgical management of patients with multiple endocrine neoplasia-2A (MEN-2A) contin...
Abstract PURPOSE: Hereditary medullary thyroid carcinoma (MTC) therapy is surgical resection. Beca...
Contains fulltext : 88633.pdf (publisher's version ) (Closed access)BACKGROUND Mul...
textabstractBackground Multiple endocrine neoplasia type 2 (MEN 2) is caused by a RET mutation in ch...
Multiple endocrine neoplasia type 2 (MEN 2) is caused by a RET mutation in chromosome 10. All MEN 2 ...
AIMS: To evaluate the value of prophylactic total thyroidectomy in multiple endocrine neoplasia 2a (...
Multiple endocrine neoplasia type 2 (MEN 2) is caused by a RET mutation in chromosome 10. All MEN 2 ...
Multiple endocrine neoplasia (MEN) syndromes are characterized by the association of various endocri...
Multiple Endocrine Neoplasia 2 (MEN2) is a hereditary cancer syndrome for developing medullary thyro...
RET proto-oncogene predisposing to multiple endocrine neoplasia type IIa (MEN-IIa) has allowed a DNA...
International audienceBackground:In hereditary medullary thyroid carcinoma (HMTC), prophylactic surg...